We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

Akero Therapeutics Inc (NASDAQ ... drug achieved ≥1 stage improvement in liver fibrosis without worsening of MASH at 96 weeks. This is compared to 15% for placebo. The results were consistent ...

Akero Therapeutics Inc. is a clinical-stage biotechnology ... a treatment for metabolic dysfunction-associated steatohepatitis, also referred to as MASH. The drug was well-received by participants ...

Metabolic dysfunction-associated steatohepatitis (MASH) is often referred to as a “silent disease,” as it typically shows no signs of symptoms in early stages. But it can come with certain ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Roche Holding AG Akt 0.65% CHF232.25B ...